Key result
Dopexamine treatment did not improve in-hospital mortality in patients undergoing major abdominal surgery and the critically ill.
Why the study?
Does dopexamine reduce in-hospital mortality in patients undergoing major abdominal surgery and in the critically ill?
Meta-Analysis (n=935)
Does dopexamine reduce in-hospital mortality in patients undergoing major abdominal surgery and in the critically ill?
Dopexamine does not significantly improve in-hospital mortality in critically ill patients or those undergoing major abdominal surgery.
Answers are grounded in this paper and cite their sources.
Dopexamine should not be used to reduce mortality in major abdominal surgery or critical illness; confirms lack of benefit in Level 1 evidence.
The objective of the study was to determine whether dopexamine alters in-hospital mortality. The following databases were searched, Embase (1974-July 2007), Medline (1950-July 2007), CINAHL, PubMed and Cochrane Clinical Register of Controlled Trials (CENTRAL). Two reviewers independently checked the quality of the studies and extracted data. Six randomised controlled trials totalling 935 patients were included. Mortality was not significantly different with dopexamine treatment (relative risk 0.75, 95% confidence interval 0.48-1.18, p = 0.22). In conclusion, dopexamine does not improve in-hospital mortality in patients undergoing major abdominal surgery and in the critically ill.
No takes yet. Share an insight, caveat, or question.
Jayakumar et al. (2009) conducted a meta-analysis in Major abdominal surgery and critically ill (n=935). Dopexamine was evaluated on In-hospital mortality (relative risk 0.75, 95% CI 0.48-1.18, p=0.22). Dopexamine treatment did not improve in-hospital mortality in patients undergoing major abdominal surgery and the critically ill.
Synapse has enriched 10 related papers. Consider them for comparative context: